论文部分内容阅读
转移的或放疗后复发的浸润性膀胱癌患者生存期很短。单一药物化疗,如氨乙喋呤或顺铂的反应率约30～40％,生存一年者不足5％。联合化疗中最有效的方案是CMV和M-VAC,后者尤为成功。但化疗的毒性很明显。作者为减少副作用而设计了新的替代方案。方法第一天给予氨甲喋呤50mg/m~2,长春花硷3mg/m~2、mitozantrone 10mg/m~2、JM8(carboplatin)200mg/m~2,第15天给予氨甲喋呤50mg/m~2,28天为一个疗程。Mitozantrone稀释于5％葡萄糖100ml中于30分钟静脉推注,然后将稀释在5％葡萄糖250ml中的JM8于30分钟给予,再静注长春花硷和氨甲喋呤。给予氨甲喋呤24小时后口服亚叶酸15mg。患者接受化疗2～4个疗程。
Patients with invasive bladder cancer who have relapsed or relapsed after radiotherapy have a very short survival time. Single-agent chemotherapy, such as acetopurine or cisplatin, has a response rate of about 30-40%, and less than 5% of those who survive for one year. The most effective protocols for combination chemotherapy are CMV and M-VAC, which is particularly successful. However, the toxicity of chemotherapy is obvious. The authors designed new alternatives to reduce side effects. Methotrexate 50 mg/m~2, vinblastine 3 mg/m~2, mitozantrone 10 mg/m~2, JM8(carboplatin) 200 mg/m~2 on the first day, methotrexate 50 mg/m~2 on the 15th day. Day is a course of treatment. Mitozantrone was diluted in 100 ml of 5% glucose in a 30-minute intravenous infusion, and then JM8 diluted in 5% glucose 250 ml was administered at 30 minutes, followed by intravenous infusion of vinca and methotrexate. Methotrexate 15 mg was administered 24 hours after methotrexate administration. The patient received chemotherapy for 2 to 4 courses.